专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2020021061A1 HUMANIZED ANTI-PD-1 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2020021061A1
公开(公告)日：2020-01-30
申请号：PCT/EP2019/070171
申请日：2019-07-26
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： BLANUSA, Milan , MACCANN, Darragh , BERGER, Sven , ROTHE, Christine , OLWILL, Shane , BOSSENMAIER, Birgit , JAQUIN, Thomas , HANSBAUER, Eva-Maria , BARTHELS, Christian
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： The disclosure provides, among other things, humanized antibodies that bind to programmed cell death protein 1 (PD-1) and compositions comprising such antibodies, whereby the antibodies and/or compositions can be useful for generating a durable anti-tumor or anti-infection response. Such antibodies can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors, or as anti-infection agents. The present disclosure also concerns methods of making the antibodies described herein as well as compositions comprising such antibodies. The present disclosure further relates to nucleic acid molecules encoding such antibodies and to methods for generation of such antibodies and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such antibodies as well as compositions comprising one or more of such antibodies.

2. 发明申请

WO2018087108A1 PROTEINS SPECIFIC FOR CD137 审中-公开
标题翻译：蛋白质特异性CD137
公开(公告)号：WO2018087108A1
公开(公告)日：2018-05-17
申请号：PCT/EP2017/078522
申请日：2017-11-08
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： HINNER, Marlon , OLWILL, Shane , EICHNER, Timo
IPC分类号： C07K14/47 , A61K38/17 , C12N5/10 , C12N15/00
CPC分类号： C07K14/47 , A61K38/00 , C07K16/2878 , C07K2317/33 , C07K2317/75 , C07K2317/92 , C07K2318/20 , C07K2319/33
摘要： The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectiousdiseases, and autoimmune diseases. The present discloser further shows the human lipocalin muteins can compete with CD137L for CD137 binding. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.
摘要翻译：本公开提供了结合CD137并可用于药物应用的人脂质运载蛋白突变蛋白，例如作为抗癌剂和/或免疫调节剂用于治疗或预防人类疾病，例如癌症，感染性疾病和自身免疫性疾病。本发明人进一步显示人脂质运载蛋白突变蛋白可以与CD137L竞争CD137结合。本公开还涉及制备本文描述的CD137结合脂质运载蛋白突变蛋白的方法以及包含此类脂质运载蛋白突变蛋白的组合物。本公开还涉及编码此类脂质运载蛋白突变蛋白的核酸分子以及用于产生此类脂质运载蛋白突变蛋白和核酸分子的方法。此外，该申请公开了这些脂质运载蛋白突变蛋白的治疗和/或诊断用途以及包含一种或多种这种脂质运载蛋白突变蛋白的组合物。

3. 发明申请

WO2020173897A1 NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 审中-公开
公开(公告)号：WO2020173897A1
公开(公告)日：2020-09-03
申请号：PCT/EP2020/054821
申请日：2020-02-25
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： BEL AIBA, Rachida Siham , BOSSENMAIER, Birgit , JAQUIN, Thomas , PEPER-GABRIEL, Janet , HANSBAUER, Eva-Maria , SCHLOSSER, Corinna , OLWILL, Shane
IPC分类号： C07K14/47 , A61P35/00 , C07K16/28 , C07K16/32 , A61K38/00
摘要： The disclosure provides fusion proteins specific for both CD137 and GPC3, which fusion protein can be used to co-stimulate lymphocyte activation in a GPC3-target-dependent manner. Such fusion proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion proteins described herein as well as compositions comprising such fusion proteins. The present disclosure further relates to nucleic acid molecules encoding such fusion proteins and to methods for generation of such fusion proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion proteins as well as compositions comprising one or more of such fusion proteins.

4. 发明申请

WO2021089588A1 HER2/4-1BB BISPECIFIC FUSION PROTEINS FOR THE TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2021089588A1
公开(公告)日：2021-05-14
申请号：PCT/EP2020/080892
申请日：2020-11-04
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： OLWILL, Shane , MATIS, Louis , BRUNS, Ingmar , DUERR, Manuela , YUSUF, Rushdia Zareen , ZETTL, Markus , ALLERSDORFER, Andrea , KASTRESANA, Aizea Morales , SCHLOSSER, Corinna
IPC分类号： A61P35/00 , C07K14/00 , C07K16/32 , A61K39/00
摘要： The disclosure provides methods and compositions for treating tumors, particularly HER2- positive tumors. The method comprises administering a therapeutically effective amount of a HER2/4-1BB bispecific fusion protein. The HER2/4-1BB bispecific fusion protein is administered at a dose of from about 2.5 mg/kg to about 27 mg/kg, once every week, once every two weeks, or once every three week

5. 发明申请

WO2020025659A1 NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 审中-公开
公开(公告)号：WO2020025659A1
公开(公告)日：2020-02-06
申请号：PCT/EP2019/070596
申请日：2019-07-31
申请人： PIERIS PHARMACEUTICALS GMBH , LES LABORATOIRES SERVIER
发明人： PAVLIDOU, Marina , PATTARINI, Lucia , SCHOLER-DAHIREL, Alix , ROTHE, Christine , OLWILL, Shane , BEL AIBA, Rachida , HINNER, Marlon , PEPER, Janet
IPC分类号： C07K16/28 , C07K14/47 , A61K38/00 , A61P35/00
摘要： The disclosure provides fusion proteins specific for both CD 137 and PD-L1, which fusion protein can be used to co-stimulate lymphocyte activation in a PD-L1-target-dependent manner. Such fusion proteins can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion proteins described herein as well as compositions comprising such fusion proteins. The present disclosure further relates to nucleic acid molecules encoding such fusion proteins and to methods for generation of such fusion proteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion proteins as well as compositions comprising one or more of such fusion proteins.

6. 发明申请

WO2018134279A1 NOVEL FUSION POLYPEPTIDES SPECIFIC FOR LAG-3 AND PD-1 审中-公开
公开(公告)号：WO2018134279A1
公开(公告)日：2018-07-26
申请号：PCT/EP2018/051150
申请日：2018-01-18
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： OLWILL, Shane , ROTHE, Christine , ALLERSDORFER, Andrea , EICHNER, Timo , BEL AIBA, Rachida Siham , JAQUIN, Thomas, Jean
IPC分类号： C07K16/28
CPC分类号： C07K16/2803 , A61K2039/505 , A61P35/00 , C07K16/2818 , C07K2317/31 , C07K2317/76 , C07K2317/94 , C07K2318/20 , C07K2319/00
摘要： The disclosure provides for fusion polypeptides specific for both immune checkpoints PD-1 and LAG-3, whereby the fusion polypeptides can be useful for generating a durable anti- tumor or anti-infection response. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors, or as anti- infection agents. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.

7. 发明申请

WO2018134274A1 LIPOCALIN MUTEINS WITH BINDING AFFINITY FOR LAG-3 审中-公开
公开(公告)号：WO2018134274A1
公开(公告)日：2018-07-26
申请号：PCT/EP2018/051139
申请日：2018-01-18
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： ROTHE, Christine , OLWILL, Shane , ALLERSDORFER, Andrea , EICHNER, Timo , BEL AIBA, Rachida Siham , PAVLIDOU, Marina
IPC分类号： C07K14/47 , A61K38/00
摘要： The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

8. 发明申请

WO2016177762A1 PROTEINS SPECIFIC FOR CD137 审中-公开
标题翻译： CD137特定蛋白质
公开(公告)号：WO2016177762A1
公开(公告)日：2016-11-10
申请号：PCT/EP2016/059959
申请日：2016-05-04
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： HINNER, Marlon , ROTHE, Christine , OLWILL, Shane , ALLERSDORFER, Andrea , BEL AIBA, Rachida Siham
IPC分类号： C07K14/47 , A61K38/17 , C12N5/10 , C12N15/00
CPC分类号： C07K14/47 , A61K38/00 , A61K47/51 , C07K2319/30
摘要： The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.
摘要翻译：本公开提供了结合CD137的人脂质运载蛋白突变蛋白，并且可以用于药物应用中，例如用作治疗或预防人类疾病如癌症，感染性疾病和自身免疫疾病的抗癌剂和/或免疫调节剂。本公开还涉及制备本文所述的CD137结合脂质运载蛋白突变蛋白的方法以及包含这种脂质运载蛋白突变蛋白的组合物。本公开还涉及编码这种脂质运载蛋白突变蛋白的核酸分子以及产生这种脂质运载蛋白突变蛋白和核酸分子的方法。此外，本申请公开了这些脂质运载蛋白突变蛋白的治疗和/或诊断用途以及包含一种或多种这样的脂质运载蛋白突变蛋白的组合物。

9. 发明申请

WO2020043683A1 COMBINATION THERAPIES COMPRISING CD137/HER2 BISPECIFIC AGENTS AND PD-1 AXIS INHIBITORS AND USES THEREOF 审中-公开
公开(公告)号：WO2020043683A1
公开(公告)日：2020-03-05
申请号：PCT/EP2019/072754
申请日：2019-08-27
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： BRUNS, Ingnar , MATIS, Louis , OLWILL, Shane , JAQUIN, Thomas
IPC分类号： A61P35/00 , C07K16/28 , C07K16/32
摘要： The disclosure provides compositions and methods for treating previously treated specific HER2-positive advanced or metastatic solid tumors. The disclosure provides compositions and methods for enhancing immune response in an individual having HER2-positive advanced or metastatic solid tumors. The method comprises administering a PD-1axis inhibitor and a bispecific agent that targets CD137 and HER2.

10. 发明申请

WO2016177802A1 ANTI-CANCER FUSION POLYPEPTIDE 审中-公开
标题翻译：抗癌融合多肽
公开(公告)号：WO2016177802A1
公开(公告)日：2016-11-10
申请号：PCT/EP2016/060041
申请日：2016-05-04
申请人： PIERIS PHARMACEUTICALS GMBH
发明人： HINNER, Marlon , ROTHE, Christine , OLWILL, Shane , BEL AIBA, Rachida, Siham , MOEBIUS, Ulrich , SCHLOSSER, Corinna , JAQUIN, Thomas, Jean
IPC分类号： C07K16/28 , A61K39/395 , C07K14/47 , C07K16/32 , C07K19/00
CPC分类号： C07K16/32 , A61K2039/505 , C07K14/435 , C07K16/2878 , C07K2317/52 , C07K2317/73 , C07K2318/20 , C07K2319/00
摘要： The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu- positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.
摘要翻译：本公开提供了对于CD137和HER2 / neu特异性的融合多肽，其融合多肽可用于引导CD137聚集和激活HER2 / neu-阳性肿瘤细胞。这种融合多肽可用于许多药物应用中，例如用作治疗或预防人类疾病如多种肿瘤的抗癌剂和/或免疫调节剂。本公开还涉及制备本文所述的融合多肽的方法以及包含这种融合多肽的组合物。本公开还涉及编码这种融合多肽的核酸分子以及用于产生这种融合多肽和核酸分子的方法。此外，本申请公开了这种融合多肽的治疗和/或诊断用途以及包含一种或多种这样的融合多肽的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式